Trial results

Young Adults With Early-onset Obesity Treated With Semaglutide

NCT05574439 on ClinicalTrials.gov · last registry update 2026-07-08

An unusually large phase 4: 246 participants, more than double the 72 typical for the stage. The sponsor logged completion for 1 April 2026. Primary outcome, as filed: Change in BMI (weight in kg/height in m^2). semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

COMPLETED

Phase

P4

Drug

semaglutide

Wegovy, Ozempic, Rybelsus

Sponsor

Signe Torekov

Sponsor type

Other

Enrollment

246

Started

2022-05-30

Primary completion

2026-04-01 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in BMI (weight in kg/height in m^2)

Conditions studied

Obesity, Adolescent

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.